Skip to content
10-Q

Quarterly Report

Y-mAbs Therapeutics, Inc.

0001558370-25-007492

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 45.28M sh
Shares Diluted Q1 2025 · Mar 31, 2025 45.1M sh
Shares Diluted Q1 2025 · Mar 31, 2024 43.78M sh
Capex Q1 2025 · Mar 31, 2025 $127K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$6.91M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.48M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $60.31M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $67.23M
Stockholders Equity Q1 2025 · Mar 31, 2025 $89.46M
Stockholders Equity Q1 2025 · Dec 31, 2024 $92M
Stockholders Equity Q1 2025 · Mar 31, 2024 $99.19M
Stockholders Equity Q1 2025 · Dec 31, 2023 $100.99M
Current Liabilities Q1 2025 · Mar 31, 2025 $18.96M
Current Liabilities Q1 2025 · Dec 31, 2024 $23.7M
Total Liabilities Q1 2025 · Mar 31, 2025 $23.16M
Total Liabilities Q1 2025 · Dec 31, 2024 $27.9M
Current Assets Q1 2025 · Mar 31, 2025 $90.45M
Current Assets Q1 2025 · Dec 31, 2024 $98.51M
Total Assets Q1 2025 · Mar 31, 2025 $112.61M
Total Assets Q1 2025 · Dec 31, 2024 $119.9M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.12
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.15
Eps Basic Q1 2025 · Mar 31, 2025 −$0.12
Eps Basic Q1 2025 · Mar 31, 2024 −$0.15
Sga Expense Q1 2025 · Mar 31, 2025 $13.09M
Sga Expense Q1 2025 · Mar 31, 2024 $11.43M
Rd Expense Q1 2025 · Mar 31, 2025 $11.36M
Rd Expense Q1 2025 · Mar 31, 2024 $13.27M
Net Income Q1 2025 · Mar 31, 2025 −$5.2M
Net Income Q1 2025 · Mar 31, 2024 −$6.63M
Operating Income Q1 2025 · Mar 31, 2025 −$6.54M
Operating Income Q1 2025 · Mar 31, 2024 −$6.91M
Gross Profit Q1 2025 · Mar 31, 2025 $17.9M
Gross Profit Q1 2025 · Mar 31, 2024 $17.83M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $3M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $2.1M
Revenue Q1 2025 · Mar 31, 2025 $20.9M
Revenue Q1 2025 · Mar 31, 2024 $19.93M